Web Exclusives

Early IONA-MM data show promising real-world evidence of the benefits of isatuximab in patients with relapsed/refractory multiple myeloma. Read Article ›

New treatment options are under consideration for consolidation and maintenance therapy after autologous stem-cell transplantation in newly diagnosed patients with multiple myeloma. Read Article ›

A single infusion of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma resulted in an overall response rate of 95%. Read Article ›

Minimal residual disease assessments are increasingly being used in the clinical trial setting. Read Article ›

Updated analysis of IKEMA showed improved responses with isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Read Article ›

Ciltacabtagene autoleucel has been shown to have compelling survival benefit, and a new study shows improved health-related quality of life in patients with triple-class exposed multiple myeloma. Read Article ›

Final analysis of ICARIA-MM supports isatuximab plus pomalidomide and dexamethasone as standard of care in patients with relapsed/refractory multiple myeloma. Read Article ›

Continuing medical education and nursing continuing professional development–approved activities can improve clinicians’ knowledge of the fast-emerging treatment landscape in multiple myeloma. Read Article ›

Daratumumab plus lenalidomide and dexamethasone showed deep clinical responses in patients who continued treatment for ≥18 months. Read Article ›

Final results from the LYRA study demonstrate daratumumab plus cyclophosphamide, bortezomib, dexamethasone was well-tolerated and effective in patients with newly diagnosed or relapsed/refractory multiple myeloma. Read Article ›

Better understanding of physician decision factors when selecting therapy for patients with refractory multiple myeloma may facilitate adoption of a wider variety of new treatment options. Read Article ›

Page 2 of 20